No Data
Reikou Bio-B (02179.HK) has completed the enrollment for the Phase III clinical trial of the new adjuvant recombinant shingles vaccine REC610.
On January 2, Gelonghui reported that esoteric Biotechnology-B (02179.HK) announced that the phase III clinical study of its independently developed new adjuvant recombinant shingles vaccine REC610 has successfully completed the enrollment of all subjects. This clinical study uses a randomized, double-blind, placebo-controlled design aimed at evaluating the protective efficacy, safety, and immunogenicity of the REC610 vaccine in healthy subjects aged 40 and above. A total of 24,640 subjects have been recruited across 18 research centers in Yunnan, Henan, and Shanxi Provinces. Shingles is a common disease caused by a latent viral infection, which can lead to complications for patients.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Jiangsu Recbio Technology Shareholders to Vote Dec. 24 on Share Issue
Express News | Jiangsu Recbio Technology - to Issue Not More Than 143.1 Mln Domestic Shares at RMB5.59 per Share
whqqq : Will they fall after a pandemic?
Spinee OP whqqq : It's hard to say![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
whqqq Spinee OP : But it can still be held for a short time, right?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")